Economic Analyses of Phase III Cooperative Cancer Group Clinical Trials: Are They Feasible?

References

• Bennett C L, Armitage J L, Buchner D, Gulati S. Economic analysis alongside phase III clinical trials in cancer. Cancer Invest 1994; 12(3)336–342
   PubMed Web of Science ®Google Scholar
• Glandon G L, Shapiro R J. Economic and quality of life outcomes: Managed care perspectives. Oncology 1995; 9(11)111–120
   PubMedGoogle Scholar
• American Society of Clinical Oncology recommendations for the use of hematopoietic growth factors. Evidence based clinical practice guidelines. J Clin Oncol 1994; 12: 2471–2508
   PubMed Web of Science ®Google Scholar
• Bennett C L, Smith T J, George S L, Hillner B E, Fleishman S, Neill H B. Free-riding and the prisoner's dilemma: Problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 1995; 13: 2457–2463
   PubMed Web of Science ®Google Scholar
• Hamblin T J. Disappointments in treating acute leukemia in the elderly. N Engl J Med 1995; 332: 1712–1713
   PubMed Web of Science ®Google Scholar
• Mayer R J, Davis R B, Schiffer C A, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Preisler H, Davis R B, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of ANLL: A CALGB study. Blood 1987; 69: 1441–1446
   PubMed Web of Science ®Google Scholar
• Rees J K, Gray R. Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of AML: MRC ninth AML trial. Semin Oncol 1987; 14: 32–37
   PubMed Web of Science ®Google Scholar
• Sebban C, Archimaud W, Coiffier B, Guoyotat S, Treille-Ritrouet D, Maupas J, Fiere D. Treatment of acute myeloid leukemia in the elderly patients. A retrospective study. Cancer 1988; 61: 227–232
   PubMed Web of Science ®Google Scholar
• Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorbicin or adriamycin for therapy of AML: A CALGB study. Blood 1982; 60: 454–459
   PubMed Web of Science ®Google Scholar
• Rowe J M, Andersen J W, Mazza J J, et al. A randomized placebo controlled phase III study of GM-CSF in adult patients with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Blood 1995; 86: 457–462
   PubMed Web of Science ®Google Scholar
• Rowe J M, Rubin A, Mazza J P, Paietta E, Anderson J W, Ghalie R, Wiernik P H. Incidence of infections in adult patients (>55 years) with acute myeloid leukemia treated with yeast-derived GM-CSF (Sargromostim): Results of a double-blind prospective study by the Eastern Cooperative Oncology Group. Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases, Hiddeman, et al. Springer-Verlag, Berlin 1996, (in press)
   Google Scholar
• Gulati S, Bennett C L. Granulocyte macrophage colony stimulating factor as an adjunct therapy for relapsed Hodgkin's disease. Ann Intern Med 1992; 116: 177–182
   PubMed Web of Science ®Google Scholar
• Shwartz M, Young D W, Siegrist R. The ratio of costs to charges: How good a basis for estimating costs?. Inquiry 1995/1996; 32: 476–481
   PubMed Web of Science ®Google Scholar
• Bennett C L, Westerman I L. Economic analysis during phase III clinical trials: Who, what, when, where, and why. Oncology 1995; 9(11)169–176
   PubMedGoogle Scholar
• Dombret H, Chasting C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332: 1678–1683
   PubMed Web of Science ®Google Scholar
• Stone R M, Berg D T, George S L, et al. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671–1677
   PubMed Web of Science ®Google Scholar
• Lobo P J, Powles R L, Hanrahan A, Reynolds D K. Acute myeloblasts; leukemia—A model for assessing value for new treatment programmes. Br Med J; 1991; 302: 323–326
   PubMed Web of Science ®Google Scholar
• Bennett C L, Armitage J L, LeSage S, Gulati S, Armitage J O, Gorin C. Economic analyses of clinical trials in cancer: Are they helpful to policy makers?. Stem Cells 1994; 12: 424–429
   PubMed Web of Science ®Google Scholar
• Bennett C L, George S L, Vose J M, et al. Granulocyte macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed lymphoid malignancy: Economic analyses of phase III clinical trials. Stem Cells 1995; 13: 414–420
   PubMed Web of Science ®Google Scholar
• Luce B R, Singer J W, Wechsler J M, et al. Recombinant human granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer: An economic analysis of a randomized, double-Mind, placebo-controlled trial. Pharmacoeconomics 1994; 6: 42–48
   PubMed Web of Science ®Google Scholar
• Bennett C L, Matchar D, McCrory D, McLeod D G, Crawford E D, Hillner B E. Cost-effectiveness models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?. Cancer 1996; 77: 1854–1861
   PubMed Web of Science ®Google Scholar